(Circulation. 1997;95:2068-2074.)
© 1997 American Heart Association, Inc.
Articles |
From the Institute of Clinical Pharmacology and Department of Angiology (K.A.), Medical School, Hannover, Germany.
Background We studied urinary nitrate and cGMP excretion rates, indices of systemic NO formation, and plasma concentrations of L-arginine and the endogenous NO synthase inhibitor asymmetrical dimethylarginine (ADMA) and its inactive stereoisomer, symmetrical dimethylarginine, in 77 patients with peripheral arterial occlusive disease (PAOD) in Fontaine stages IIb through IV and in 47 young and 37 elderly healthy control subjects.
Methods and Results Urinary nitrate excretion was 182.0±11.4 µmol/mmol creatinine and cGMP excretion was 186.2±13.0 nmol/mmol creatinine in young healthy control subjects. In elderly control subjects, both excretion rates were slightly lower (nitrate, 156.0±7.8 µmol/mmol creatinine; cGMP, 150.0±8.3 nmol/mmol creatinine; P=NS). In PAOD patients, there was a significant, progressive reduction of urinary nitrate (IIb, 138.4±11.9; III, 128.6±11.3; and IV, 91.9±8.0 µmol/mmol creatinine; P<.05) and cGMP (IIb, 139.9±25.2; III, 115.6±13.1; and IV, 76.9±7.9 nmol/mmol creatinine; P<.05) excretion rates related to the Fontaine stage of PAOD. These changes were independent of changes in renal excretory function. Plasma L-arginine concentrations were not significantly different between the groups, but ADMA concentrations were elevated in PAOD patients (young control subjects, 1.25±0.11; elderly control subjects, 1.01±0.05 µmol/L; IIb, 2.62±0.24; III, 3.06±0.48; and IV, 3.49±0.26 µmol/L; P<.05 for PAOD versus control subjects). There was a significant linear correlation between urinary nitrate and cGMP excretion rates and a significant negative linear correlation between plasma ADMA concentrations and urinary nitrate excretion.
Conclusions In PAOD patients, there is a progressive reduction in urinary nitrate and cGMP excretion rates, which may be caused in part by accumulation of ADMA, an endogenous inhibitor of NO synthase.
Key Words: hypercholesterolemia atherosclerosis endothelium-derived factors risk factors
This article has been cited by other articles:
![]() |
T. Leong, D. Zylberstein, I. Graham, L. Lissner, D. Ward, J. Fogarty, C. Bengtsson, C. Bjorkelund, D. Thelle, and for The Swedish-Irish-Norwegian (SIN) Collaboratio Asymmetric Dimethylarginine Independently Predicts Fatal and Nonfatal Myocardial Infarction and Stroke in Women: 24-Year Follow-Up of the Population Study of Women in Gothenburg Arterioscler. Thromb. Vasc. Biol., May 1, 2008; 28(5): 961 - 967. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Game, J. Allard, G. Escourrou, P. Gourdy, I. Tack, P. Rischmann, J.-F. Arnal, and B. Malavaud Estradiol increases urethral tone through the local inhibition of neuronal nitric oxide synthase expression Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2008; 294(3): R851 - R857. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Lucke, N. Kanzelmeyer, K. Chobanyan, D. Tsikas, D. Franke, M. J. Kemper, J. H.H. Ehrich, and A. M. Das Elevated asymmetric dimethylarginine (ADMA) and inverse correlation between circulating ADMA and glomerular filtration rate in children with sporadic focal segmental glomerulosclerosis (FSGS) Nephrol. Dial. Transplant., February 1, 2008; 23(2): 734 - 740. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Park, H. Itoh, K. Yamahara, M. Sone, K. Miyashita, N. Oyamada, N. Sawada, D. Taura, M. Inuzuka, T. Sonoyama, et al. Therapeutic Potential of Atrial Natriuretic Peptide Administration on Peripheral Arterial Diseases Endocrinology, February 1, 2008; 149(2): 483 - 491. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Matsumoto, S. Ueda, S.-i. Yamagishi, K. Matsuguma, R. Shibata, K. Fukami, H. Matsuoka, T. Imaizumi, and S. Okuda Dimethylarginine Dimethylaminohydrolase Prevents Progression of Renal Dysfunction by Inhibiting Loss of Peritubular Capillaries and Tubulointerstitial Fibrosis in a Rat Model of Chronic Kidney Disease J. Am. Soc. Nephrol., May 1, 2007; 18(5): 1525 - 1533. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Toth, A. Racz, P. M. Kaminski, M. S. Wolin, Z. Bagi, and A. Koller Asymmetrical Dimethylarginine Inhibits Shear Stress-Induced Nitric Oxide Release and Dilation and Elicits Superoxide-Mediated Increase in Arteriolar Tone Hypertension, March 1, 2007; 49(3): 563 - 568. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Mittermayer, K. Krzyzanowska, M. Exner, W. Mlekusch, J. Amighi, S. Sabeti, E. Minar, M. Muller, M. Wolzt, and M. Schillinger Asymmetric Dimethylarginine Predicts Major Adverse Cardiovascular Events in Patients With Advanced Peripheral Artery Disease Arterioscler. Thromb. Vasc. Biol., November 1, 2006; 26(11): 2536 - 2540. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Billecke, L. A. Kitzmiller, J. J. Northrup, S. E. Whitesall, M. Kimoto, A. V. Hinz, and L. G. D'Alecy Contribution of whole blood to the control of plasma asymmetrical dimethylarginine Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1788 - H1796. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Fetalvero, M. Shyu, A. P. Nomikos, Y.-F. Chiu, R. J. Wagner, R. J. Powell, J. Hwa, and K. A. Martin The prostacyclin receptor induces human vascular smooth muscle cell differentiation via the protein kinase A pathway Am J Physiol Heart Circ Physiol, April 1, 2006; 290(4): H1337 - H1346. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sahin, C. Arslan, M. Naziroglu, S. E. Tunc, M. Demirci, R. Sutcu, and N. Yilmaz Asymmetric Dimethylarginine and Nitric Oxide Levels as Signs of Endothelial Dysfunction in Behcet's Disease Ann. Clin. Lab. Sci., January 1, 2006; 36(4): 449 - 454. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Reimann, J. Dierkes, A. Carlsohn, D. Talbot, M. Ferrari, J. Hallund, W. L. Hall, K. Vafeiadou, U. Huebner, F. Branca, et al. Consumption of Soy Isoflavones Does Not Affect Plasma Total Homocysteine or Asymmetric Dimethylarginine Concentrations in Healthy Postmenopausal Women J. Nutr., January 1, 2006; 136(1): 100 - 105. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Carello, S. E. Whitesall, M. C. Lloyd, S. S. Billecke, and L. G. D'Alecy Asymmetrical dimethylarginine plasma clearance persists after acute total nephrectomy in rats Am J Physiol Heart Circ Physiol, January 1, 2006; 290(1): H209 - H216. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. K Oka, A. Szuba, J. C Giacomini, and J. P Cooke A pilot study of l-arginine supplementation on functional capacity in peripheral arterial disease Vascular Medicine, November 1, 2005; 10(4): 265 - 274. [Abstract] [PDF] |
||||
![]() |
R. Schnabel, S. Blankenberg, E. Lubos, K. J. Lackner, H. J. Rupprecht, C. Espinola-Klein, N. Jachmann, F. Post, D. Peetz, C. Bickel, et al. Asymmetric Dimethylarginine and the Risk of Cardiovascular Events and Death in Patients With Coronary Artery Disease: Results from the AtheroGene Study Circ. Res., September 2, 2005; 97(5): e53 - e59. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Perticone, A. Sciacqua, R. Maio, M. Perticone, R. Maas, R. H. Boger, G. Tripepi, G. Sesti, and C. Zoccali Asymmetric Dimethylarginine, L-Arginine, and Endothelial Dysfunction in Essential Hypertension J. Am. Coll. Cardiol., August 2, 2005; 46(3): 518 - 523. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Qureshi, H. Chen, A. T Brown, R. Fitzgerald, X. Zhang, J. Breckenridge, R. Kazi, A. J Crocker, M. C Stuhlingexsr, K. Lin, et al. Homocysteine-induced vascular dysregulation is mediated by the NMDA receptor Vascular Medicine, August 1, 2005; 10(3): 215 - 223. [Abstract] [PDF] |
||||
![]() |
R. E. Girgis, H. C. Champion, G. B. Diette, R. A. Johns, S. Permutt, and J. T. Sylvester Decreased Exhaled Nitric Oxide in Pulmonary Arterial Hypertension: Response to Bosentan Therapy Am. J. Respir. Crit. Care Med., August 1, 2005; 172(3): 352 - 357. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. T. Kielstein, S. M. Bode-Boger, G. Hesse, J. Martens-Lobenhoffer, A. Takacs, D. Fliser, and M. M. Hoeper Asymmetrical Dimethylarginine in Idiopathic Pulmonary Arterial Hypertension Arterioscler. Thromb. Vasc. Biol., July 1, 2005; 25(7): 1414 - 1418. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. P Cooke ADMA: its role in vascular disease Vascular Medicine, May 1, 2005; 10(2_suppl): S11 - S17. [Abstract] [PDF] |
||||
![]() |
R. H Boger Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials Vascular Medicine, May 1, 2005; 10(2_suppl): S19 - S25. [Abstract] [PDF] |
||||
![]() |
R. H Boger, E. Schwedhelm, R. Maas, S. Quispe-Bravo, and C. Skamira ADMA and oxidative stress may relate to the progression of renal disease: rationale and design of the VIVALDI study Vascular Medicine, May 1, 2005; 10(2_suppl): S97 - S102. [Abstract] [PDF] |
||||
![]() |
S. Ziegler, F. Mittermayer, C. Plank, E. Minar, M. Wolzt, and G.-H. Schernthaner Homocyst(e)ine-Lowering Therapy Does Not Affect Plasma Asymmetrical Dimethylarginine Concentrations in Patients with Peripheral Artery Disease J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2175 - 2178. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Koga, Y. Akita, J. Nishioka, S. Yatsuga, N. Povalko, Y. Tanabe, S. Fujimoto, and T. Matsuishi L-Arginine improves the symptoms of strokelike episodes in MELAS Neurology, February 22, 2005; 64(4): 710 - 712. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Krzyzanowska, F. Mittermayer, H.-P. Kopp, M. Wolzt, and G. Schernthaner Weight Loss Reduces Circulating Asymmetrical Dimethylarginine Concentrations in Morbidly Obese Women J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6277 - 6281. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Scalera, J. Borlak, B. Beckmann, J. Martens-Lobenhoffer, T. Thum, M. Tager, and S. M. Bode-Boger Endogenous Nitric Oxide Synthesis Inhibitor Asymmetric Dimethyl L-Arginine Accelerates Endothelial Cell Senescence Arterioscler. Thromb. Vasc. Biol., October 1, 2004; 24(10): 1816 - 1822. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. H. Boger Asymmetric Dimethylarginine, an Endogenous Inhibitor of Nitric Oxide Synthase, Explains the "L-Arginine Paradox" and Acts as a Novel Cardiovascular Risk Factor J. Nutr., October 1, 2004; 134(10): 2842S - 2847S. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Nijveldt, M. P. C. Siroen, T. Teerlink, and P. A. M. van Leeuwen Elimination of Asymmetric Dimethylarginine by the Kidney and the Liver: A Link to the Development of Multiple Organ Failure? J. Nutr., October 1, 2004; 134(10): 2848S - 2852S. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Suda, M. Tsutsui, T. Morishita, H. Tasaki, S. Ueno, S. Nakata, T. Tsujimoto, Y. Toyohira, Y. Hayashida, Y. Sasaguri, et al. Asymmetric Dimethylarginine Produces Vascular Lesions in Endothelial Nitric Oxide Synthase-Deficient Mice: Involvement of Renin-Angiotensin System and Oxidative Stress Arterioscler. Thromb. Vasc. Biol., September 1, 2004; 24(9): 1682 - 1688. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Momohara, S. Sakamoto, S. Obayashi, T. Aso, M. Goto, and H. Azuma Roles of endogenous nitric oxide synthase inhibitors and endothelin-1 for regulating myometrial contractions during gestation in the rat Mol. Hum. Reprod., July 1, 2004; 10(7): 505 - 512. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Sydow, B. Hornig, N. Arakawa, S. M Bode-Boger, D. Tsikas, T. Munuzel, and R. H Boger Endothelial dysfunction in patients with peripheral arterial disease and chronic hyperhomocysteinemia: potential role of ADMA Vascular Medicine, May 1, 2004; 9(2): 93 - 101. [Abstract] [PDF] |
||||
![]() |
J. P. Cooke Asymmetrical Dimethylarginine: The Uber Marker? Circulation, April 20, 2004; 109(15): 1813 - 1818. [Full Text] [PDF] |
||||
![]() |
Y. Higashi, M. Kimura, K. Hara, K. Noma, D. Jitsuiki, K. Nakagawa, T. Oshima, K. Chayama, T. Sueda, C. Goto, et al. Autologous Bone-Marrow Mononuclear Cell Implantation Improves Endothelium-Dependent Vasodilation in Patients With Limb Ischemia Circulation, March 16, 2004; 109(10): 1215 - 1218. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. T. Kielstein, B. Impraim, S. Simmel, S. M. Bode-Boger, D. Tsikas, J. C. Frolich, M. M. Hoeper, H. Haller, and D. Fliser Cardiovascular Effects of Systemic Nitric Oxide Synthase Inhibition With Asymmetrical Dimethylarginine in Humans Circulation, January 20, 2004; 109(2): 172 - 177. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Nijveldt, T. Teerlink, C. van Guldener, H. A. Prins, A. A. van Lambalgen, C. D. A. Stehouwer, J. A. Rauwerda, and P. A. M. van Leeuwen Handling of asymmetrical dimethylarginine and symmetrical dimethylarginine by the rat kidney under basal conditions and during endotoxaemia Nephrol. Dial. Transplant., December 1, 2003; 18(12): 2542 - 2550. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Osanai, M. Saitoh, S. Sasaki, H. Tomita, T. Matsunaga, and K. Okumura Effect of Shear Stress on Asymmetric Dimethylarginine Release From Vascular Endothelial Cells Hypertension, November 1, 2003; 42(5): 985 - 990. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. H Boger The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor Cardiovasc Res, October 1, 2003; 59(4): 824 - 833. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. T. Kielstein, S. M. Bode-Boger, J. C. Frolich, E. Ritz, H. Haller, and D. Fliser Asymmetric Dimethylarginine, Blood Pressure, and Renal Perfusion in Elderly Subjects Circulation, April 15, 2003; 107(14): 1891 - 1895. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ueda, S. Kato, H. Matsuoka, M. Kimoto, S. Okuda, M. Morimatsu, and T. Imaizumi Regulation of Cytokine-Induced Nitric Oxide Synthesis by Asymmetric Dimethylarginine: Role of Dimethylarginine Dimethylaminohydrolase Circ. Res., February 7, 2003; 92(2): 226 - 233. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Sydow, E. Schwedhelm, N. Arakawa, S. M. Bode-Boger, D. Tsikas, B. Hornig, J. C. Frolich, and R. H. Boger ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins Cardiovasc Res, January 1, 2003; 57(1): 244 - 252. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Hermenegildo, P. Medina, M. Peiro, G. Segarra, J. M. Vila, J. Ortega, and S. Lluch Plasma Concentration of Asymmetric Dimethylarginine, an Endogenous Inhibitor of Nitric Oxide Synthase, Is Elevated in Hyperthyroid Patients J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5636 - 5640. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. De Bree, W. M. M. Verschuren, D. Kromhout, L. A. J. Kluijtmans, and H. J. Blom Homocysteine Determinants and the Evidence to What Extent Homocysteine Determines the Risk of Coronary Heart Disease Pharmacol. Rev., December 1, 2002; 54(4): 599 - 618. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Maas, E. Schwedhelm, J. Albsmeier, and R. H Boger The pathophysiology of erectile dysfunction related to endothelial dysfunction and mediators of vascular function Vascular Medicine, August 1, 2002; 7(3): 213 - 225. [Abstract] [PDF] |
||||
![]() |
R. A. Mangiafico, L. S. Malatino, T. Attina, R. Messina, and C. E. Fiore Exaggerated Endothelin Release in Response to Acute Mental Stress in Patients with Intermittent Claudication Angiology, July 1, 2002; 53(4): 383 - 390. [Abstract] [PDF] |
||||
![]() |
H. Masuda, T. Tsujii, T. Okuno, K. Kihara, M. Goto, and H. Azuma Accumulated endogenous NOS inhibitors, decreased NOS activity, and impaired cavernosal relaxation with ischemia Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2002; 282(6): R1730 - R1738. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Stuhlinger, F. Abbasi, J. W. Chu, C. Lamendola, T. L. McLaughlin, J. P. Cooke, G. M. Reaven, and P. S. Tsao Relationship Between Insulin Resistance and an Endogenous Nitric Oxide Synthase Inhibitor JAMA, March 20, 2002; 287(11): 1420 - 1426. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Silvestro, G. Oliva, and G. Brevetti Intermittent claudication and endothelial dysfunction Eur. Heart J. Suppl., March 1, 2002; 4(suppl_B): B35 - B40. [Abstract] [PDF] |
||||
![]() |
P. Perrone-Filardi and M. Chiariello Coronary artery disease and intermittent claudication: how to manage the patient Eur. Heart J. Suppl., March 1, 2002; 4(suppl_B): B58 - B62. [Abstract] [PDF] |
||||
![]() |
R. O. Cannon III Oral L-arginine (and other active ingredients) for ischemic heart disease? J. Am. Coll. Cardiol., January 2, 2002; 39(1): 46 - 48. [Full Text] [PDF] |
||||
![]() |
J. T. Kielstein, R. H. Boger, S. M. Bode-Boger, J. C. Frolich, H. Haller, E. Ritz, and D. Fliser Marked Increase of Asymmetric Dimethylarginine in Patients with Incipient Primary Chronic Renal Disease J. Am. Soc. Nephrol., January 1, 2002; 13(1): 170 - 176. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. M. Matata and M. Galinanes Effect of Diabetes on Nitric Oxide Metabolism During Cardiac Surgery Diabetes, November 1, 2001; 50(11): 2603 - 2610. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. T. Kielstein, J. C. Frolich, H. Haller, and D. Fliser ADMA (asymmetric dimethylarginine): an atherosclerotic disease mediating agent in patients with renal disease? Nephrol. Dial. Transplant., September 1, 2001; 16(9): 1742 - 1745. [Full Text] [PDF] |
||||
![]() |
P. Lundman, M. J. Eriksson, M. Stuhlinger, J. P. Cooke, A. Hamsten, and P. Tornvall Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine J. Am. Coll. Cardiol., July 1, 2001; 38(1): 111 - 116. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. G. Lamping and F. M. Faraci Role of Sex Differences and Effects of Endothelial NO Synthase Deficiency in Responses of Carotid Arteries to Serotonin Arterioscler. Thromb. Vasc. Biol., April 1, 2001; 21(4): 523 - 528. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Gielen, G. Schuler, and R. Hambrecht Exercise Training in Coronary Artery Disease and Coronary Vasomotion Circulation, January 2, 2001; 103 (1): e1 - e6. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. H. Boger, S. M. Bode-Boger, P. S. Tsao, P. S. Lin, J. R. Chan, and J. P. Cooke An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2287 - 2295. [Abstract] [Full Text] [PDF] |
||||
![]() |
P R J Ames, C Tommasino, J Alves, J D Morrow, L Iannaccone, G Fossati, S Caruso, F Caccavo, and V Brancaccio Antioxidant susceptibility of pathogenic pathways in subjects with antiphospholipid antibodies: a pilot study Lupus, November 1, 2000; 9(9): 688 - 695. [Abstract] [PDF] |
||||
![]() |
G. Wu and C. J. Meininger Arginine Nutrition and Cardiovascular Function J. Nutr., November 1, 2000; 130(11): 2626 - 2629. [Abstract] [Full Text] [PDF] |
||||
![]() |